ReviewPathophysiology of bladder dysfunction in Parkinson's disease
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder associated with loss of dopaminergic neurons. The prevalence rate estimates of PD ranged from 65.6 per 100,000 to 12,500 per 100,000. In addition to motor symptoms, patients with PD often show non-motor symptoms. The non-motor problems of PD include neuropsychiatric disorders, sleep disorders, sensory symptoms, and autonomic disorders (Goldstein et al., 2011). Bladder dysfunction is one of the most common autonomic disorders (Jain, 2011, Sakakibara et al., 2008c), the incidence being estimated as 55–80%. Studies have shown that the bladder dysfunction has great significance in relation to quality-of-life measures, early institutionalization, and health economics (McGrother et al., 1990, Sakakibara et al., 2001b). It is particularly important to note that, unlike motor disorder, bladder dysfunction is sometimes non-responsive to levodopa, suggesting that they occur through a complex patho-physiology (Uchiyama et al., 2003). This is because pathology of PD is not confined to the degeneration of dopaminergic neurons in the substantia nigra, and involves other locations in the brain and other neurotransmitter systems than the dopaminergic system. For this reason, add-on therapy is required to maximize patients' quality of life. This article reviews patho-physiology of bladder dysfunction in PD, with particular reference to neural control of the bladder, symptoms, objective assessment, and treatment.
Section snippets
Normal micturition and detrusor overactivity
The lower urinary tract (LUT) consists of two major components, the bladder and urethra. The bladder has abundant muscarinic M2,3 receptors and adrenergic beta 3 receptors, and is innervated by cholinergic (parasympathetic) and noradrenergic (sympathetic) fibers for contraction and relaxation, respectively (de Groat, 2006). The urethra has abundant adrenergic alpha 1A/D receptors and nicotinic receptors, and is innervated by noradrenergic (sympathetic; contraction) and cholinergic (somatic;
Basal ganglia circuit and dopamine
The net effect of the basal ganglia on micturition is thought to be inhibitory (Fig. 2) (de Groat, 2006, Seki et al., 2001, Yoshimura et al., 1998, Yoshimura et al., 2003). Functional neuroimaging during bladder filling results in activation in the globus pallidus of normal volunteers (Nour et al., 2000) and in the putamen in patients with PD (Kitta et al., 2006). In contrast, dopamine transporter imaging was lower in PD patients with urinary dysfunction than in those without it (Sakakibara et
Lower urinary tract symptoms
The reported prevalence of LUT symptoms (LUTS) in patients with PD ranges from 38% to 71% (Andersen, 1985, Berger et al., 1987, Gray et al., 1995, Hald and We, 1982, Hattori et al., 1992, Murnaghan, 1961). However, it has been difficult to determine to what extent PD contributes to LUTS. Men older than 60 years of age may have bladder outlet obstruction due to prostate hyperplasia. Women may have stress urinary incontinence. “Idiopathic DO” (Abrams et al., 2002) may occur in men and women older
Dopaminergic drugs
It is possible that levodopa and other antiparkinson medication may affect bladder function in PD. Aranda and Cramer (1993) studied the effects of 3–8 mg apomorphine injection on the storage function in 2 de novo PD patients, and found that the bladder capacity increased. They gave oral levodopa to one of the patients, and the bladder capacity increased. We compared the frequency of bladder dysfunction in de novo PD and PD with levodopa. In that study, LUTS was less frequent than in the treated
Conclusions
This article reviewed the current concepts of bladder dysfunction in PD. Central nervous system pathology is clearly associated with bladder dysfunction (urinary urgency/frequency) in PD. Anticholinergic agents are the choice to treat bladder dysfunction that does not easily penetrate the BBB. These treatments are beneficial in maximizing patients' quality of life.
References (123)
- et al.
Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms
J. Urol.
(2000) - et al.
Effect of levodopa on urinary bladder
Urology
(1976) - et al.
Urodynamic findings in Parkinson's disease
J. Urol.
(1987) - et al.
The pontine micturition center projects to sacral cord GABA immunoreactive neurons in the cat
Neurosci. Lett.
(1997) - et al.
Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease
J. Urol.
(2006) - et al.
Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease
J. Urol.
(2003) - et al.
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy
J. Urol.
(2009) - et al.
The dopamine neurotoxin 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset
Neurosci. Lett.
(1986) - et al.
Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease
Brain Res.
(1990) - et al.
Neuronal excitation in the ventral tegmental area modulates the micturition reflex mediated via the dopamine D(1) and D(2) receptors in rats
J. Pharmacol. Sci.
(2003)
Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs
Brain Res.
Effects of electrical stimulation of the raphe area on the micturition reflex in cats
Neuroscience
Multi-organ autonomic dysfunction in Parkinson disease
Parkinsonism Relat. Disord.
Brain activation during detrusor overactivity in patients with parkinson's disease: a PET study
J. Urol.
Central muscarinic receptor subtypes regulating voiding in rats
J. Urol.
Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease
Parkinsonism Relat. Disord.
Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients
Parkinsonism Relat. Disord.
Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease
Urology
Micturition-related neuronal firing in the periaqueductal gray area in cats
Neuroscience
Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms?
Parkinsonism Relat. Disord.
Role of glutamate and NMDA receptors in the descending limb of the spinobulbospinal micturition reflex pathway of the rat
Neurosci. Lett.
Levodopa motor complications in Parkinson's disease
Trend Neurosci.
Neurourologic findings in Parkinson's disease
J. Urol.
Benign prostatic obstruction and Parkinson's disease—should transurethral resection of the prostate be avoided?
J. Urol.
Impact of Parkinson's disease on continence after radical prostatectomy
Urology
Micturitional disturbance and pontine tegmental lesion; urodynamic and MRI analyses of the vascular cases
J. Neurol. Sci.
Firing patterns of micturition-related neurons in the pontine storage centre in cats
Auton. Neurosci.
Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats
Auton. Neurosci.
Effects of subthalamic nucleus stimulation on the micturation reflex in cats
Neuroscience
Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease
Auton. Neurosci.
SPECT imaging of the dopamine transporter with [123I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction
J. Neurol. Sci.
Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly
Clin. Ther.
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
Br. J. Pharmacol.
Standardisation Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society
Neurourol. Urodyn.
Disturbances of bladder and urethral function in Parkinson's disease
Int. Urol. Nephrol.
Mechanisms of disease: central nervous system involvement in overactive bladder syndrome
Nat. Clin. Pract. Urol.
Lesions of the anterior frontal lobes and disturbances of micturition and defaecation
Brain
The cerebral control of micturition
Proc. Roy Soc. Med.
Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score
J. Neurol. Neurosurg. Psychiatry
Effect of apomorphine and l-dopa on the Parkinsonian bladder
Neurourol. Urodyn.
Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors
J. Neurol.
Pontine pathology and voiding dysfunction
Br. J. Urol.
The central control of micturition and continence: implications for urology
Br. J. Urol. Int.
Effects of inhibitory rTMS on bladder function in Parkinson's disease patients
Mov. Disord.
Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease
Neurology
Urinary symptoms in Parkinson's disease: prevalence and associated factors
Arq. Neuropsiquiatr.
How to recognize patients with Parkinsonism who should not have urological surgery
Br. J. Urol.
Role of subcutaneous apomorphine in parkinsonian voiding dysfunction
Lancet
Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective
Neurology
The biochemical basis of neuropharmacology
Cited by (92)
Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinson's disease
2024, International Review of NeurobiologyLevodopa/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson's disease: hitting two birds with one stone?
2023, Parkinsonism and Related DisordersA time-course study of urodynamic analyses in rat models with dopaminergic depletion induced through unilateral and bilateral 6-hydroxydopamine injections
2023, Journal of the Formosan Medical AssociationThe relationship between lower urinary tract function and <sup>123</sup>ioflupane scintigraphy in drug-naïve Parkinson's disease
2021, Autonomic Neuroscience: Basic and ClinicalCitation Excerpt :The micturition reflex is under the influence of both DA (inhibitory in D1 and facilitatory in D2) and GABA (strictly inhibitory) (de Groat, 2006; Tai et al., 2009). Both the SNc neuronal firing and the released striatal DA seem to activate the DA D1-GABAergic direct pathway, which inhibits the basal ganglia output nuclei; it may also inhibit the micturition reflex by a GABAergic collateral to the periaqueductal gray micturition circuit (Sakakibara et al., 2012), or by the striatal-frontal pathways (Yamamoto et al., 2009). Noninvasive neuroimaging of PD patients by PET/SPECT has been performed to correlate the images with postmortem nigral cell counts, to measure the progression of degenerating nigrostriatal cells in vivo, and to correlate reduced nigrostriatal dopaminergic function in PD.